Thermo Fisher Scientific Inc.
TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3025% above fair value
$682.65−14.35 (-2.06%)
Close on Nov 2, 2026Market cap $252.41BP/E 36.0Yield 0.25%
Thermo Fisher Scientific GAAP R&D % of Total Revenue by Year
GAAP R&D % of Total Revenue (%)
Thermo Fisher Scientific GAAP R&D % of Total Revenue: 3.1% in FY2025, down 0.1 pts from a year earlier.
Latest, FY2025
3.1%
Period ended Dec 31, 2025
Change on a year earlier
-0.1 pts
3.2% in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Where the FY2025 figure comes from
“GAAP R&D expense 1,337 3.1 % 1,390 3.2 % 1,397 3.1 %”
Source: Q3 2026 Reconciliation of Financial Information ↗
Reported in IR Financial Reconciliation Package.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP R&D % of Total Revenue (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.1% | -0.1 pts | Q3 2026 Reconciliation of Financial Information ↗ |
| FY2024 | Dec 31, 2024 | 3.2% | +0.1 pts | Q3 2026 Reconciliation of Financial Information ↗ |
| FY2023 | Dec 31, 2023 | 3.1% | -0.2 pts | Q3 2026 Reconciliation of Financial Information ↗ |
| FY2022 | Dec 31, 2022 | 3.3% | -0.3 pts | Q4 & FY2025 Reconciliation of Financial Information ↗ |
| FY2021 | Dec 31, 2021 | 3.6% | – | Q4 & FY2024 Reconciliation of Financial Information ↗ |
Cite this data
StockData. (2026). Thermo Fisher Scientific GAAP R&D % of Total Revenue (%), annual FY2021–FY2025 [Data set]. Compiled from Thermo Fisher Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/tmo/kpis/gaap-rd-reconcil-pct
See every metric in the Thermo Fisher Scientific KPI table. Data updated Oct 29, 2026.